IGF-1 Growth Factor Testing: Principles, Methods, and Clinical Applications

IGF-1 (Insulin-like Growth Factor-1) testing is a fundamental laboratory measurement used to evaluate growth hormone axis activity, diagnose growth disorders, and monitor endocrine therapies. This comprehensive technical guide covers the biological principles of IGF-1, sample requirements, analytical methods, clinical applications, and frequently asked questions. It is written for clinicians, laboratory professionals, and researchers seeking a reliable reference on IGF-1 measurement.

Technical Overview

Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a 70-amino acid peptide hormone with a molecular weight of approximately 7.6 kDa. Structurally homologous to proinsulin, IGF-1 functions as the principal mediator of growth hormone (GH) action. It is produced primarily by the liver in response to GH stimulation from the anterior pituitary gland, and it is also synthesized locally in many tissues where it acts in an autocrine and paracrine manner.

In circulation, more than 99% of IGF-1 is bound to a family of six high-affinity insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), with IGFBP-3 serving as the most abundant carrier protein in a ternary complex with the acid-labile subunit (ALS). This binding extends the functional half-life of IGF-1 to approximately 12 to 16 hours, in sharp contrast to the highly pulsatile secretion pattern of GH.

Because serum IGF-1 concentrations integrate GH secretion over an extended period and remain relatively stable throughout the day, IGF-1 measurement serves as a reliable indirect indicator of mean GH output. This stability makes the IGF-1 assay a cornerstone test in the evaluation of short stature, growth hormone deficiency, acromegaly, and other disorders of the GH–IGF axis.

Testing Samples

Serum

Serum is the recommended and most widely used sample type for IGF-1 measurement. Venous blood is collected into a serum separator tube (SST) or plain red-top tube, allowed to clot for 30 minutes at room temperature, and then centrifuged. A minimum serum volume of 0.5 mL is typically required, although automated platforms may need less. Fasting is not strictly required because IGF-1 is minimally affected by acute food intake, though morning collection is preferred to reduce pre-analytical variability.

Plasma

EDTA or heparinized plasma may be acceptable for certain assay platforms, provided the method has been validated by the manufacturer for that matrix. Laboratories should confirm sample type compatibility before submitting plasma specimens, as matrix-dependent biases have been documented between serum and plasma results.

Sample Handling and Storage

IGF-1 is a stable analyte due to its binding proteins. Serum samples can be stored at 2–8°C for up to 72 hours before analysis. For longer storage, samples should be frozen at -20°C or below, preferably at -70°C for extended periods. Repeated freeze-thaw cycles should be avoided. Severe hemolysis, lipemia, or icterus may interfere with some immunoassay platforms and should be noted during specimen rejection criteria evaluation.

Testing Items

The primary analyte measured is total serum IGF-1, which reflects the overall concentration of IGF-1 released from binding proteins during pre-treatment. Additional related measurements may be ordered as part of a comprehensive growth axis evaluation:

• Total IGF-1: the standard clinical measurement for growth axis assessment
• Free or bioavailable IGF-1: measured in specific research and clinical contexts to assess unbound, biologically active hormone
• IGFBP-3: the principal binding protein, sometimes ordered alongside IGF-1 to improve diagnostic accuracy in pediatric populations
• Growth hormone (GH): often measured in combination or through dynamic stimulation and suppression testing
• Acid-labile subunit (ALS): used in specialized evaluations of ternary complex disorders

Interpretation requires age-specific and sex-specific reference intervals, as IGF-1 concentrations rise progressively through childhood, peak during puberty, and decline steadily with advancing age. Results are frequently expressed as standard deviation scores (SDS) relative to normative data for accurate clinical interpretation.

Testing Methods

Modern IGF-1 measurement relies primarily on automated immunoassays and mass spectrometry. A critical pre-analytical step in all immunoassay formats is the dissociation of IGF-1 from its binding proteins, typically achieved through acid-ethanol extraction or acidification with subsequent neutralization. Without this pre-treatment, IGFBPs interfere substantially with antibody binding and produce falsely low results.

Chemiluminescent Immunoassay (CLIA)

CLIA is the dominant method on high-throughput automated platforms in clinical laboratories. It offers rapid turnaround time, excellent precision, wide dynamic range, and full automation from pre-treatment to signal detection. Most contemporary CLIA systems incorporate acid dissociation steps onboard and are calibrated against the WHO International Standard (NIBSC 02/254) to improve inter-method harmonization.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA remains a widely used manual or semi-automated technique, particularly in research settings and smaller laboratories. Competitive and sandwich ELISA formats are both available, with sandwich formats preferred for specificity. ELISA provides good analytical sensitivity but requires careful attention to manual pre-treatment, incubation conditions, and washing steps.

Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS)

LC-MS/MS is increasingly regarded as the reference method for IGF-1 quantification. Following immunoextraction or solid-phase extraction and tryptic digestion, multiple reaction monitoring provides direct molecular measurement with high specificity and minimal antibody cross-reactivity. LC-MS/MS demonstrates superior inter-laboratory agreement and is valuable for standardizing results across immunoassay platforms.

Radioimmunoassay (Historical)

Early radioimmunoassay (RIA) methods played an important historical role in establishing IGF-1 reference data but have been largely replaced by non-isotopic automated techniques due to radioactive waste handling requirements and longer turnaround times.

Applications

IGF-1 measurement supports a broad range of clinical, forensic, and research applications:

• Evaluation of short stature and growth failure in children, including screening for growth hormone deficiency
• Diagnosis and post-treatment monitoring of acromegaly and gigantism, where IGF-1 serves as the most sensitive single marker of disease activity
• Assessment of growth hormone insensitivity syndromes such as Laron syndrome, characterized by elevated GH with low IGF-1
• Monitoring of recombinant human GH (rhGH) replacement therapy and dose adjustment in both pediatric and adult patients
• Surveillance of biochemical control during acromegaly treatment with somatostatin analogs, GH receptor antagonists, or surgery
• Assessment of nutritional status, hepatic synthetic function, and chronic disease states, since IGF-1 is highly nutrition- and liver-dependent
• Anti-doping testing in elite sport, where IGF-1 is used as a biomarker in combination with other markers to detect GH abuse
• Epidemiological and clinical research into aging, metabolic syndrome, cancer risk, and longevity

FAQ

Is fasting required before an IGF-1 test?

Fasting is not strictly required because IGF-1 levels are not significantly altered by acute meals. However, morning collection is recommended to minimize variability, and patients should inform the laboratory of any medications, particularly estrogen therapy or GH injections, that may affect results.

What does a high IGF-1 result mean?

Elevated IGF-1 suggests excessive growth hormone secretion and is strongly associated with acromegaly in adults and gigantism in children. Physiological elevations occur during puberty and pregnancy. A high result should be confirmed and followed by an oral glucose suppression test and pituitary imaging when clinically indicated.

What does a low IGF-1 result mean?

Low IGF-1 may indicate growth hormone deficiency, malnutrition, chronic liver disease, hypothyroidism, poorly controlled diabetes, or celiac disease. In children with suspected deficiency, confirmation requires GH stimulation testing, as IGF-1 alone cannot definitively establish the diagnosis.

Can IGF-1 testing alone diagnose growth disorders?

No. IGF-1 is an excellent screening and monitoring marker, but definitive diagnosis of GH deficiency or excess requires dynamic stimulation or suppression tests, such as insulin tolerance, glucagon stimulation, or oral glucose tolerance tests, interpreted together with clinical findings and imaging studies.

How long does it take to receive IGF-1 test results?

Results are typically available within 1 to 3 business days for automated immunoassay platforms. Mass spectrometry-based testing and reference laboratory referrals may require additional time, usually 5 to 10 business days.

What factors can affect IGF-1 test accuracy?

Key influencing factors include age, sex, pubertal stage, pregnancy, nutritional status, hepatic and renal function, oral estrogen administration, diabetes control, and assay-specific differences between laboratory platforms. Results should always be interpreted against method-specific, age-matched and sex-matched reference intervals.